HOUSTON--(BUSINESS WIRE)--IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback